Pharmacological inhibition of HSP90 with 17-AAG or genetic silencing of ENO1 reverses USP21-mediated glycolytic activation and proliferative advantage, confirming the critical roles of the USP21–HSP90–HIF1α and USP21–ENO1 axes in CCA progression. This evidence concerns the gene ENO1 and cholangiocarcinoma.